Hematopoietic lineage cell‑specific protein 1 immunoreactivity indicates an increased risk of poor overall survival in patients with ovarian carcinoma.

MLA

Liu, WeNting, et al. “Hematopoietic Lineage Cell‑specific Protein 1 Immunoreactivity Indicates an Increased Risk of Poor Overall Survival in Patients with Ovarian Carcinoma.” Oncology Letters, vol. 15, no. 6, June 2018, pp. 9406–12. EBSCOhost, https://doi.org/10.3892/ol.2018.8493.

APA

Liu, Wen., Kajiyama, H., Shibata, K., Koya, Y., SENga, T., & Kikkawa, F. (2018). Hematopoietic lineage cell‑specific protein 1 immunoreactivity indicates an increased risk of poor overall survival in patients with ovarian carcinoma. Oncology Letters, 15(6), 9406–9412. https://doi.org/10.3892/ol.2018.8493

Chicago

Liu, WeNting, Hiroaki Kajiyama, Kiyosumi Shibata, Yoshihiro Koya, Takeshi SENga, and Fumitaka Kikkawa. 2018. “Hematopoietic Lineage Cell‑specific Protein 1 Immunoreactivity Indicates an Increased Risk of Poor Overall Survival in Patients with Ovarian Carcinoma.” Oncology Letters 15 (6): 9406–12. doi:10.3892/ol.2018.8493.